pCMV-iNOS Vector

A plasmid capable of delaying tumour growth (Adams et al., 2009), useful in cardiovascular studies or any physiology associated with vasodilation.

Contributors

Inventor Institute
Helen McCarthy Queen's University Belfast
SKU: 153287
Product description: pCMV-iNOS Plasmid is a human nitric oxide synthase (iNOS) transgene driven by a constitutively active CMV (cytomegalovirus) promoter. Originally developed as an anti-cancer therapeutic with a view to a gene therapy strategies that address hormone refractory prostate cancer (HRPC). Studies in the literature have demonstrated that this plasmid is capable of delaying tumour growth (Adams et al., 2009). The plasmid serves as a useful tool in cardiovascular studies or any physiology associated with vasodilation.
Alternate name: Nitric Oxide Synthase
Cat. #: 153287
Tool sub type: pcDNA 3.1
Research Fields: Cancer; Metabolism; Neurobiology
Target: Inducible Nitric Oxide Synthase
Bacterial resistance: Kanamycin
Application notes: Recommended for transformation in DH5 alpha bacterial cells, iNOS gene is 4.4kb
Shipping conditions: Dry Ice
References:

Adams et al. 2009. J Gene Med. 11(2):160-8. PMID: 19062185.

Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells.

Coulter et al. 2008. Gene Ther. 15(7):495-503. PMID: 18256696.

The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.

McCarthy et al. 2007. J Gene Med. 9(6):511-20. PMID: 17471586.

Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with spec…

Related Tools for Vectors

Cat. # Tool Name
153288 phOC-iNOS Vector Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.